Sanofi: Depressive Disorder, Major trials
The registry lists 14 Depressive Disorder, Major studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive DisorderCompletedNCT01606384Phase 2
- A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive DisorderCompletedNCT01034995Phase 2
- Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive DisorderCompletedNCT00855530Phase 3
- Efficacy and Safety of SR58611 Compared to Placebo and ParoxetineCompletedNCT00825058Phase 3
- Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and ParoxetineCompletedNCT00825019Phase 3
- An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly PatientsCompletedNCT00822744Phase 2
- An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive DisorderCompletedNCT00629551Phase 3
- An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive DisorderCompletedNCT00531622Phase 3
- Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive DisorderCompletedNCT00432614Phase 3
- An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive DisorderCompletedNCT00415142Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)CompletedNCT00385307Phase 3
- A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive DisorderCompletedNCT00345098Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedNCT00252356Phase 3
- Efficacy and Safety of SR58611A in Patients With Major Depressive DisorderCompletedNCT00252330Phase 3